Dabrafenib Completed Phase 2 Trials for Melanoma Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Completed | Treatment | 2 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT01682213 | Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation | |
| NCT01153763 | A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma | |
| NCT01619774 | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor |